Buspirone as a Candidate Medication for Methamphetamine Abuse
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Methamphetamine use disorders are an unrelenting public health concern. Intensive research
efforts have yielded behavioral interventions that reduce methamphetamine use, however, these
interventions are not universally effective and treatment effects diminish over time.
Development of a pharmacotherapy that enhances the efficacy of these interventions is a
priority for the National Institute on Drug Abuse. This study proposes to determine the
impact of buspirone maintenance on self-administration of methamphetamine. These preliminary
data will be used to support further research developing buspirone as a pharmacotherapy for
methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate
the reinforcing effects of methamphetamine.